"OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT" [vol 21, pg S3, 2021]

被引：0

作者：

Ocio, Enrique M. ^{[1
]}

Perrot, Aurore ^{[2
]}

Bories, Pierre ^{[3
]}

San-Miguel, Jesus F. ^{[4
]}

Blau, Igor W. ^{[5
]}

Karlin, Lionel ^{[6
]}

Martinez-Lopez, Joaquin ^{[7
]}

Ponisch, Wolfram ^{[8
]}

Bringhen, Sara ^{[9
]}

Marcatti, Magda ^{[10
]}

Mateos, Maria-Victoria ^{[11
]}

Rodriguez-Otero, Paula ^{[4
]}

LeRoux, Nadia ^{[12
]}

Dong, Yvonne ^{[13
]}

Macc, Sandrine ^{[12
]}

Fitzmaurice, Thomas ^{[14
]}

Moreau, Philippe ^{[15
]}

机构：

[1] Univ Cantabria, Santander, Spain

[2] Univ Toulouse, CHU Toulouse, IUCT O, UPS,Serv Hematol, Toulouse, France

[3] Toulouse Univ, Inst Canc Oncopole, Toulouse, France

[4] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[5] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[6] Ctr Hosp Lyon Sud, Serv Hematol Clin, Pierre Benite, France

[7] Univ Complutense Madrid, Hosp 12 Octubre, CNIO, Dept Hematol, Madrid, Spain

[8] Univ Leipzig, Leipzig, Germany

[9] Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy

[10] Univ Vita Salute San Raffaele, Milan, Italy

[11] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain

[12] Sanofi, Vitry Sur Seine, France

[13] Sanofi, R&D, Beijing, Peoples R China

[14] Sanofi, Cambridge, MA USA

[15] Univ Hosp Nantes, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 06期

关键词：

D O I：

10.1016/j.clml.2022.03.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：425 / 425

页数：1

共 2 条

[1] Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT
Ocio, Enrique
Perrot, Aurore
Bories, Pierre
San-Miguel, Jesus F.
Blau, Igor W.
Karlin, Lionel
Martinez-Lopez, Joaquin
Ponisch, Wolfram
Bringhen, Sara
Marcatti, Magda
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Le Roux, Nadia
Dong, Yvonne
Mace, Sandrine
Fitzmaurice, Thomas
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S3 - S4
[2] Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study
Ocio, Enrique M.
Perrot, Aurore
Bories, Pierre
San-Miguel, Jesus F.
Blau, Igor W.
Karlin, Lionel
Martinez-Lopez, Joaquin
Ponisch, Wolfram
Bringhen, Sara
Ciceri, Fabio
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Le Roux, Nadia
Dong, Yvonne
Fitzmaurice, Thomas
Oprea, Corina
Moreau, Philippe
BLOOD, 2020, 136

← 1 →